HC Wainwright Lowers Aptose Biosciences (NASDAQ:APTO) Price Target to $2.00

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its target price reduced by stock analysts at HC Wainwright from $7.00 to $2.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock.

Separately, StockNews.com started coverage on shares of Aptose Biosciences in a research note on Wednesday, November 13th. They set a “hold” rating for the company.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $0.24 on Wednesday. The company has a market cap of $4.42 million, a P/E ratio of -0.09 and a beta of 1.26. Aptose Biosciences has a 1 year low of $0.23 and a 1 year high of $2.91. The firm has a 50-day simple moving average of $0.38 and a two-hundred day simple moving average of $0.62.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.